{"nctId":"NCT01900444","briefTitle":"Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea","startDateStruct":{"date":"2013-07-11","type":"ACTUAL"},"conditions":["Japanese Encephalitis"],"count":119,"armGroups":[{"label":"IMOJEV Group","type":"EXPERIMENTAL","interventionNames":["Biological: IMOJEV"]}],"interventions":[{"name":"IMOJEV","otherNames":["Japanese Encephalitis Chimeric Virus Vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Must have participated in study JEC12 and received 1 dose of IMOJEV at least 12 months before booster vaccination\n* Age 2 to 4 years on the day of inclusion\n* In good general health at the time of inclusion\n* Informed Concent Form signed and dated by parent(s) or another legally acceptable representative(s)\n* Subject and parent(s)/legally acceptable representative(s) able to attend all scheduled visits and comply with all study procedures.\n\nExclusion Criteria:\n\n* Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical study investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the study vaccination\n* Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response\n* Previous vaccination against flavivirus disease, including JE, with another vaccine, except with IMOJEV® while participating in JEC12\n* Administration of any anti-viral within 2 months preceding Visit 1 and up to the 4 weeks following the study vaccination\n* Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following the trial vaccination, except for inactivated influenza vaccination, which may be received at least 2 weeks before the study vaccine\n* History of central nervous system disorder or disease, including seizures\n* Planned receipt of any JE vaccine during the course of the study\n* History of flavivirus infection (confirmed either clinically, serologically or virologically)\n* Administration of systemic corticosteroids for more than 2 consecutive weeks within the 4 weeks preceding vaccination\n* Thrombocytopenia, contraindicating vaccination\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating vaccination\n* Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection 3 days before vaccination as well as the day of vaccination, according to Investigator judgment. A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided\n* In an emergency setting or hospitalized involuntarily\n* Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"2 Years","maximumAge":"4 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With JE Seroprotection Before and Following a Booster Dose of IMOJEV Given One Year After Primary Immunization","description":"JE virus neutralizing antibodies were measured using a 50% plaque reduction neutralization test (PRNT50). Seroprotection status for antibody levels against JE virus before and after IMOJEV vaccination was defined as antibody titers ≥ 10 (1/dilution).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With JE Seroconversion Following a Booster Dose of IMOJEV Given One Year After Primary Immunization","description":"JE virus neutralizing antibodies were measured using PRNT50. Seroconversion was defined as a pre-vaccination titer \\<10 (1/dilution) and post-vaccination titer ≥10 (1/dilution, or pre-vaccination titer ≥10 (1/dilution) and a ≥4-fold increase of titers from pre- to post-vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titers of JE Virus Antibodies Following a Booster Dose of IMOJEV Given One Year After Primary Immunization","description":"JE virus neutralizing antibodies were measured using PRNT50 test.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"165","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8482","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Following a Booster Dose of IMOJEV Given One Year After Primary Immunization","description":"JE virus neutralizing antibodies were measured using PRNT50.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With JE Seroprotection Before and After a Booster Dose of IMOJEV Given At Different Intervals After Primary Immunization","description":"JE virus neutralizing antibodies were measured using PRNT50. Seroprotection was defined as neutralizing antibody titer ≥ 10 (1/dilution).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With JE Seroconversion Following a Booster Dose of IMOJEV Given At Different Intervals After Primary Immunization","description":"JE virus neutralizing antibodies were measured using PRNT50. Seroconversion was defined as a pre-vaccination titer \\<10 (1/dilution) and post-vaccination titer ≥10 (1/dilution, or pre-vaccination titer ≥10 (1/dilution) and a ≥4 fold increase from pre- to post-vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titers of JE Virus Antibodies Following a Booster Dose of IMOJEV At Different Intervals After Primary Immunization","description":"JE virus neutralizing antibodies were measured using PRNT50.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8850","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10240","spread":null}]}]}]},{"type":"PRIMARY","title":"Summary of Geometric Mean Titer Ratios of JE Virus Antibodies Following a Booster Dose of IMOJEV Given At Different Intervals After Primary Immunization","description":"JE virus neutralizing antibodies were measured using PRNT50.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"512","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":119},"commonTop":["Malaise","Injection site Pain","Nasopharyngitis","Myalgia","Headache"]}}}